ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc (RXRX)

6.13
-0.46
(-6.98%)
Closed March 10 3:00PM
6.00
-0.13
(-2.12%)
After Hours: 6:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
6.00
Bid
5.98
Ask
6.03
Volume
23,900,822
5.93 Day's Range 6.41
5.60 52 Week Range 12.36
Market Cap
Previous Close
6.59
Open
6.38
Last Trade
10
@
6.02
Last Trade Time
Financial Volume
US$ 146,606,036
VWAP
6.1339
Average Volume (3m)
23,741,594
Shares Outstanding
286,640,833
Dividend Yield
-
PE Ratio
-5.35
Earnings Per Share (EPS)
-1.14
Revenue
44.58M
Net Profit
-328.07M

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery... Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Recursion Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RXRX. The last closing price for Recursion Pharmaceuticals was US$6.59. Over the last year, Recursion Pharmaceuticals shares have traded in a share price range of US$ 5.60 to US$ 12.36.

Recursion Pharmaceuticals currently has 286,640,833 shares outstanding. The market capitalization of Recursion Pharmaceuticals is US$1.89 billion. Recursion Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.35.

Recursion Pharmaceuticals (RXRX) Options Flow Summary

Overall Flow

Bullish

Net Premium

57k

Calls / Puts

150.00%

Buys / Sells

125.00%

OTM / ITM

66.67%

Sweeps Ratio

0.00%

RXRX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.87-23.76111817037.877.895.95236702596.49421391CS
4-1.69-21.97659297797.6912.365.95338476248.80175828CS
12-1.1-15.49295774657.112.365.93237415947.98061096CS
26-0.16-2.59740259746.1612.365.6148820097.64118474CS
52-5.35-47.136563876711.3512.365.6100450867.84987499CS
156-1.44-19.35483870977.4416.7454.5452520258.61415339CS
260-24-803042.814.5442466389.18376988CS

RXRX - Frequently Asked Questions (FAQ)

What is the current Recursion Pharmaceuticals share price?
The current share price of Recursion Pharmaceuticals is US$ 6.00
How many Recursion Pharmaceuticals shares are in issue?
Recursion Pharmaceuticals has 286,640,833 shares in issue
What is the market cap of Recursion Pharmaceuticals?
The market capitalisation of Recursion Pharmaceuticals is USD 1.89B
What is the 1 year trading range for Recursion Pharmaceuticals share price?
Recursion Pharmaceuticals has traded in the range of US$ 5.60 to US$ 12.36 during the past year
What is the PE ratio of Recursion Pharmaceuticals?
The price to earnings ratio of Recursion Pharmaceuticals is -5.35
What is the cash to sales ratio of Recursion Pharmaceuticals?
The cash to sales ratio of Recursion Pharmaceuticals is 39.36
What is the reporting currency for Recursion Pharmaceuticals?
Recursion Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Recursion Pharmaceuticals?
The latest annual turnover of Recursion Pharmaceuticals is USD 44.58M
What is the latest annual profit for Recursion Pharmaceuticals?
The latest annual profit of Recursion Pharmaceuticals is USD -328.07M
What is the registered address of Recursion Pharmaceuticals?
The registered address for Recursion Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Recursion Pharmaceuticals website address?
The website address for Recursion Pharmaceuticals is www.recursion.com
Which industry sector does Recursion Pharmaceuticals operate in?
Recursion Pharmaceuticals operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HMRHeidmar Maritime Holdings Corporation
US$ 2.5599
(69.53%)
37.57M
RDFNRedfin Corporation
US$ 9.76
(67.70%)
92.49M
CKPTCheckpoint Therapeutics Inc
US$ 3.9895
(61.52%)
60.89M
STSSSharps Technology Inc
US$ 0.4399
(48.26%)
591.34M
PTGXProtagonist Therapeutics Inc
US$ 55.91
(45.79%)
5.09M
APEDSTKd 100 percent MSTR and 100 percent COIN ETF
US$ 11.591
(-35.98%)
2.58k
SXTCChina SXT Pharmaceuticals Inc
US$ 2.78
(-35.54%)
162.75k
PCLAPicoCELA Inc
US$ 0.8499
(-35.12%)
866.6k
CONLGraniteShares ETF Trust GraniteShares
US$ 15.685
(-34.86%)
8.63M
MSTXTidal Trust II Defiance Daily Target 2x Long MSTR ETF
US$ 19.22
(-32.95%)
24.05M
STSSSharps Technology Inc
US$ 0.4399
(48.26%)
591.61M
NVDANVIDIA Corporation
US$ 106.98
(-5.07%)
364.12M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7.3701
(-30.86%)
258.67M
TSLATesla Inc
US$ 222.15
(-15.43%)
188.57M
TQQQProShares UltraPro QQQ
US$ 59.81
(-11.27%)
155.18M

RXRX Discussion

View Posts
Monksdream Monksdream 2 days ago
You have a point

πŸ‘οΈ0
bwrbad bwrbad 6 days ago
Cross road,
πŸ‘οΈ0
bwrbad bwrbad 2 weeks ago
can RXRX - star get realignment with ,,,, - asking NVDA's AI brain & Cathy's unknown brain
πŸ‘οΈ0
3antar 3antar 2 weeks ago
Noted. You are so kind
πŸ‘οΈ0
peza77 peza77 2 weeks ago
Hopelessly overvalued, overhyped AI stuff.
ZERO approved products
If this drops to $3, it could still be over-valued
πŸ‘οΈ0
bwrbad bwrbad 2 weeks ago
dark green like black
πŸ‘οΈ0
bwrbad bwrbad 3 weeks ago
Big volume -- could be green EOD
πŸ‘οΈ0
bwrbad bwrbad 3 weeks ago
once cross 36 - it is open sky.
everyday dips are the advantage point
buying the $200 -$300 /sh stock of 2025 at $11 -$36
πŸ‘οΈ0
bwrbad bwrbad 3 weeks ago
could move $3 -$5 today
πŸ‘οΈ0
bwrbad bwrbad 3 weeks ago
You have to have skin in the game!

Reflecting back on #JPM2024 last week and this shot has to be a personal highlight. I was comparing company tattoos with NVIDIA founder & CEO Jensen Huang when @RecursionPharma Board Chair @RMartinChavez dropped his full sleeve Turing machine!… pic.twitter.com/yDPuFVmQ7u— Chris Gibson (@RecursionChris) January 16, 2024
πŸ‘οΈ0
TucsonPhil TucsonPhil 3 weeks ago
I'd wager that undisclosed information is at play, but that wouldn't be legal, so couldn't possibly be the case.
πŸ‘οΈ0
3antar 3antar 3 weeks ago
So why do you think it keeps going higher! 
πŸ‘οΈ0
bwrbad bwrbad 3 weeks ago
blindfold buy at 20 - 30 then the jump 100 - 200
πŸ‘οΈ0
bwrbad bwrbad 3 weeks ago
RXRX
πŸ‘οΈ0
TucsonPhil TucsonPhil 3 weeks ago
They announce a mixed shelf (dilution), and the price spikes?
πŸ‘οΈ0
bwrbad bwrbad 4 weeks ago
RXRX just started little little sprinting step before planting the pole and jump over that record high pole vault bar
👍 1
bwrbad bwrbad 4 weeks ago
invest - - soon --- before out of reach.
πŸ‘οΈ0
bwrbad bwrbad 4 weeks ago
this is a stock will gain 200-300% in a single day-- but today - no - it will go back to +3c or -3c in 1h
πŸ‘οΈ0
TucsonPhil TucsonPhil 1 month ago
This level of result, will make this company fly:

https://www.globenewswire.com/news-release/2025/02/05/3021646/0/en/Recursion-Presents-Phase-2-Data-for-REC-994-in-CCM-in-Late-Breaking-Oral-Presentation-at-the-International-Stroke-Conference.html
👍️ 1
bwrbad bwrbad 1 month ago
generative AI in making medical miracle
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
REC-994 MRI-based brainstem lesion volume reduction : place a $M maker brick now
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
70 institution 30 public--that's how RXRX drug working now
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
YouTube influencer position - write or call cGibson@recursion.com
πŸ‘οΈ0
TucsonPhil TucsonPhil 1 month ago
Exactly, when we see the lending fees start to rise, then I will buy more. Brokers always make money, even when investors lose.
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
they all do etard fidal TDA, but that gives the opportunity to buy low. This RxRx defines the future of MED world in AI stage- just buying little little within affordability. definitively it will grow like MSTF GOOG AAPL NVDA AMZN.., All drug lords pfizer, j&j eli, merck roche AZ BMS are lining up behind, just give few months to a year for first $100
πŸ‘οΈ0
TucsonPhil TucsonPhil 1 month ago
Fidelity is loaning shares to shorts.
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
next piece of clinical update will take it above 20 and after that it is in different league.
πŸ‘οΈ0
bwrbad bwrbad 1 month ago
Sure looks like early days of ISRG ILMN,
πŸ‘οΈ0
TucsonPhil TucsonPhil 2 months ago
Nvidia invested $50M in this company. ARK is a holder. This will be huge, once their first find gets FDA approval, and proof of concept is secured.
👍️ 1
bwrbad bwrbad 2 months ago
interesting no posters in this
future $200 - $300 stock, and that future not far - see the quality of clinical data, target diseases, and the time it took to reach there - not standard 20 ys but 3y to ph3 and a large advancing failure resistant AI powered pipeline
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
change of heart -going up.
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
rxrx WORLD
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
promised to accumulate 10k shares before Q end and hold for years. predict this issue never go BK, do RS, and one day go beyond 200+ like established big cap security issues.
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
bandwagon
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
believe in miracle ----- come to RXRX------
πŸ‘οΈ0
TucsonPhil TucsonPhil 2 months ago
Looks like Lilly is late to the party.

https://www.statnews.com/2025/01/10/eli-lilly-andreessen-horowitz-500-million-venture-fund-ai-focus/
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
cursion-re-cursion in flame after FDA REC 3565 blessings
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
Gibson🤢🥵🥶😷Gibson
πŸ‘οΈ0
bwrbad bwrbad 2 months ago
baby nvda
👍 1
bwrbad bwrbad 2 months ago
balding haircut at RXRX
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
RXRX, under $7
πŸ‘οΈ0
bwrbad bwrbad 3 months ago
out for now, let CEO work his magic if he has one under his sleeve
πŸ‘οΈ0
bwrbad bwrbad 3 months ago
is something wrong with RxRx, it looked promising based on what said to public. but something not right. ground shaken up. - like trouble.
what wrong with the CEO. if this continues that is bad sign for future of the company and the CEO.
πŸ‘οΈ0
bwrbad bwrbad 3 months ago
RXRX
πŸ‘οΈ0
bwrbad bwrbad 3 months ago
RxRx partnership: GOOG NVDA MSFT Roche/Genentech Bayer Bristol Myers Squibb Sanofi Merck ......
👍 1
bwrbad bwrbad 3 months ago
RxRx M&A: Valence –Cyclica - Exscientia
Valence – a leader in generative AI and deep learning models
Cyclica - a deep learning engine that predicts the polypharmacology of small molecules in drug discovery.
Exscientia - AI-driven precision medicine
RXRX - Regenerative AI - TechBio powerhouse
undergoing post merger reorganization, some job cuts
enough cash to fund through 2027
Ark Q3 2024 Stake: $215.9 million
Hedge Fund Investors Q3 2024:: 16
more than ten drugs in trials.
πŸ‘οΈ0
bwrbad bwrbad 3 months ago
market up big and RxRx ignored,
if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.
πŸ‘οΈ0
TucsonPhil TucsonPhil 3 months ago
RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.
👍️ 1
bwrbad bwrbad 3 months ago
Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
Shares Outstanding 6 388.94M; Float 8 252.42M
clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

% Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%
👍️ 1
JJ8 JJ8 3 months ago
Rxrx share price Long Tail Up since 06 Dec 2024.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock